From scimedweb from mail.com Sat Sep 5 05:51:28 2009 From: scimedweb from mail.com (scimedweb) Date: Sat Sep 5 10:42:32 2009 Subject: [Bioforum] Molecular Therapy of Breast Cancer: Classicism Meets Modernity (book) Message-ID: NEW BOOK ! (September 2009) Molecular Therapy of Breast Cancer: Classicism Meets Modernity (by Marc Lacroix) Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0 (hardcover): https://www.novapublishers.com/catalog/product_info.php?produc= ts_id=3D10042 (online book): https://www.novapublishers.com/catalog/product_info.php?prod= ucts_id=3D11919 Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. Despite their proven efficacy, classical therapies are, however, unable to cure metastatic breast cancer and are often associated with significant toxicity and side-effects, due to a wide spectrum of action. During the last years, our increasing knowledge of the molecular pathways underlying cancer development has led to the introduction of new drugs, of which most are directed towards very specific targets. Rather than to be used as single agents, these =93modern=94 compounds could ultimately be combined with =93classical=94 molecules. Here are described nearly 150 drugs that are currently (2009) used in routine therapy or are in clinical trials in breast cancer patients. >From the classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin, epirubin, docetaxel, paclitaxel=85, to the more recently introduced ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab=85, they also include capecitabine, gemcitabine, trastuzumab, fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of tumor-induced osteolysis, insulin-like growth factor-I receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many others. This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity. Table of Contents: Chapter 1. Introduction Chapter 2. Selective estrogen receptor modulators (SERMs) and down- regulators (SERDs) Chapter 3. Aromatase inhibitors Chapter 4. Agents inducing ovarian suppression Chapter 5. Antimetabolites Chapter 6. Alkylating agents Chapter 7. Anthracyclines Chapter 8. Microtubule-binding agents Chapter 9. Topoisomerase inhibitors Chapter 10. HER family inhibitors Chapter 11. Angiogenesis inhibitors Chapter 12. Insulin-like growth factor-I receptor inhibitors Chapter 13. RAS-RAF-MEK-ERK pathway inhibitors Chapter 14. Ubiquitin-proteasome system inhibitors Chapter 15. Histone deacetylases inhibitors Chapter 16. Mitotic inhibitors Chapter 17. Inhibitors of heat-shock proteins 90 and 27 Chapter 18. PI3K/AKT/mTOR pathway inhibitors Chapter 19. Cyclooxygenase-2 inhibitors Chapter 20. Poly(ADP-ribose) polymerase (PARP)-1 inhibitors Chapter 21. Tumor-induced osteolysis inhibitors Chapter 22. Vaccines and immunomodulators Chapter 23. Varia Index List of drugs/compounds discussed in the book: ABT-888, ABT-869, Ad-sig-hMUC-1/ecdCD40L vaccine, AE37 peptide/GM-CSF vaccine, Aflibercept, AFP464, AG014699, Alendronate, Aldesleukin, Allogeneic GM-CSF-secreting breast cancer vaccine, ALT-801, AMG 386, AMG 479, Anastrozole, Apricoxib, ARRY-334543, AS1402, ATN-224, Autologous dendritic cell-adenovirus p53 vaccine, AV-951, AVE1642, AVX701, AZD0530, AZD6244, Bavituximab, Belinostat, Bevacizumab, BGT226, BIBW 2992, BMS-754807, Bortezomib, Bosutinib, BSI-201, Busulfan, BZL101, Capecitabine, Carboplatin, CDX-1307, Celecoxib, Cetuximab, CHP-HER2, CHP-NY-ESO-1, Cisplatin, Cixitumumab, Clodronate, CNF2024, CR011-vcMMAE, Cyclophosphamide, Dasatinib, Deforolimus, Denileukin diftitox, Denosumab, Docetaxel, Doxorubicin, Entinostat, Enzastaurin, Epirubicin, Eribulin , Erlotinib, Ertumaxomab, Etoposide, Everolimus, Exemestane, Falimarev, Figitumumab, Fluorouracil, Fulvestrant, Gefitinib, Gemcitabine, Goserelin, GP2 peptide/GM-CSF vaccine, GRN163L, GSK1059615, HER2/neu (extracellular domain) peptide vaccine, hTERT/Survivin Multi-Peptide Vaccine, Ibandronate, Ifosfamide, Imatinib, IMP321, Inalimarev, Interleukin-12, Irinotecan, Ispinesib, Ixabepilone, Lapatinib, Larotaxel, Letrozole, Leuprolide, Lonafarnib, Lonaprisan, Mammaglobin-A DNA vaccine, Melphalan, Methotrexate, MK0646, MK-0752, MLN8237, Modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine, Neratinib, NVP-AUY922, NVP-BEZ235, Odanacatib, OGX-427, Olaparib, OSI-906, Ovarian Cancer Peptide Mix Immunotherapeutic Vaccine, Oxaliplatin, Paclitaxel, Panobinostat, Patupilone, Pazopanib, PD-0332991, Pemetrexed, Pertuzumab,Picoplatin, pNGVL3-hICD vaccine, PTC299, Ramucirumab, Recombinant fowlpox-CEA(6D)/ TRICOM vaccine, Recombinant vaccinia-CEA(6D)-TRICOM vaccine, Retaspimycin, Rexin-G, Risedronate, Sagopilone, SCH 727965, Sialyl Lewis=AA-keyhole limpet hemocyanin (KLH) conjugate vaccine, Sirolimus, Sorafenib, Sunitinib, Tamoxifen, Telomerase: 540-548 peptide vaccine, Temozolomide, Temsirolimus, Tesmilifene, Thiotepa, Tipifarnib, Toremifene, Trabectedin, Trastuzumab, Trastuzumab-MCC-DM1, Triptorelin, TTK peptide (mixed with adjuvant Montanide ISA-51), Valproic Acid, Vandetanib, Vinflunine, Vinorelbine, Vorinostat, WX-671, Zoledronic Acid From Heather.Vincent from manchester.ac.uk Wed Sep 16 01:10:14 2009 From: Heather.Vincent from manchester.ac.uk (Heather Vincent) Date: Wed Sep 16 07:10:48 2009 Subject: [Bioforum] Distance courses in bioinformatics and computational biology Message-ID: <4AB08146.7080104@manchester.ac.uk> At the University of Manchester, UK, we have over 10 years experience in running a range of online courses in computational biology. These courses are designed to enable biologists and computer scientists to update their skills while remaining in the workplace. They are also very suitable for home study, helping you to keep in touch with a research environment while taking a career break. The courses beginning on 5 October 2009 include: Introduction to Bioinformatics Bioinformatics for Systems Biology 'Introduction for Bioinformatics' covers the methods for sequence data. It would be a useful course for people interested in areas such as metagenomics or multi-locus sequence typing. We are also have funding from the BBSRC to develop new courses in computational systems biology. The first of these courses, Bioinformatics for Systems Biology, is running in October. It will be followed by : Mathematics for metabolic modelling Computational simulation and analysis of biochemical networks You will find further information, including fees and a link to the online application form, here: http://octette.cs.man.ac.uk/bioinformatics/index.html If you have any questions, or need advice on the module options, please contact Heather.Vincent@manchester.ac.uk From Robin.Haw from oicr.on.ca Tue Sep 22 16:03:58 2009 From: Robin.Haw from oicr.on.ca (Robin Haw) Date: Tue Sep 22 16:45:18 2009 Subject: [Bioforum] Reactome Pathway Database User Survey Message-ID: Reactome is committed to providing access to high-quality pathway information and helpful data analysis tools. With this in mind, we are actively soliciting comments from the research community in order to assess community needs. We are interested to hear about your experience with Reactome, and would like to know a bit about your background and research interests so that we can continue to improve the Reactome site and tools. You can access the survey at: http://tinyurl.com/l48zzq Thank you for taking part. Robin Haw Manager of Reactome Outreach Outreach [at] reactome.org http://www.reactome.org